Memolan (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors. By blocking excessive calcium entry caused by prolonged glutamate stimulation, it reduces neuronal excitotoxicity while allowing normal synaptic activity, which supports cognitive function in Alzheimer’s disease.

The dosage of Memolan is determined by the prescribing clinician based on the patient’s clinical condition, renal function and tolerability. The prescriber will set the appropriate strength and dosing schedule according to current medical guidelines.

Safety data for memantine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Memolan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Memolan (memantine) belongs to the NMDA receptor antagonist class, differing from acetylcholinesterase inhibitors such as donepezil. While both improve cognition, memantine is typically used in moderate to severe stages and may have a lower incidence of gastrointestinal side effects compared with some cholinesterase inhibitors.

Memolan should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Memolan is taken orally, usually as a tablet, with or without food. The exact administration schedule is set by the prescriber, who may start with a low dose and titrate upward based on tolerability and therapeutic response.

Serious risks include seizures, severe cardiac arrhythmias, hepatic injury, and rare skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for any new or worsening neurological or dermatological symptoms and seek immediate medical attention if they occur.

Memolan is contraindicated in patients with known hypersensitivity to memantine or any component of the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or significant cardiac disease, and it should be avoided in those where the risk outweighs potential benefit.